If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
"Contact to index case" means Human-to-Human transmission. I'm sure you understand camels were not involved when one patient passed to 2 others in a healthcare facility. Whether camels were involved as a first step will pale into insignificance if more human-to-human cases are contact traced.
And no, it is not " reasonable to assume that if there was going to be a wider outbreak it would have happened by now" According to the NIH , the extent of asymptomatic MERS-CoV cases is about 10% from different studies.
Finally in case it slipped your mind, the company we are invested in, Synairgen, have already conducted pre-clinical research of SNG001 showing the inhibition of Middle East Respiratory Syndrome-Coronavirus in cell-based assays.
Thanks Fruits. Always interested in the MERS situation. The report - whether deliberately or not - leaves out the clear evidence that cases 2 and 3 are contact infections of the index case ( He was in A&E with case 3 and shared a room with case 2 ) a 56 year old male school teacher - but it's still important to find his original point of infection. It will ultimately lead back to the dromedaries that carry MERS. They say he had no direct contact with the animals so he may be a secondary infection, which means there could have been others. He fell ill on 29th March and idea on 7th April, so it's reasonable to assume that if there was going to be a wider outbreak it would have happened by now. Still of concern but no epedemiological changes between cases and as WHO says - for now no need to change the threat level from Low. Newspapers like scary headlines and saying there are 3 non-camels linked cases makes it sound very scary indeed.
https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON516
Https://www.telegraph.co.uk/global-health/science-and-disease/mers-outbreak-saudi-arabia-middle-east-respiratory-syndrome/
“The health analytic firm Airfinty, which monitors disease outbreaks globally, said there was a “high threat” for the city Riyadh.
“Mers-CoV [is] still around and still a threat,” Prof Peter Horby, director of the Pandemic Sciences Institute at the University of Oxford said on X. “[Saudi Arabia] has great experience of detecting and controlling health-care associated MERS transmission – other places are less aware and less prepared. ”
Indeed Mr Costs
From such small drops, great floods (and fortunes) do burst forth into our world.
Yes, that £160 trade on close was very telling today.
5p?
someone paid close to 7p today.
Monday might be interesting.
I topped up after reading brands post.
This is my last top up, news soon I hope
Good effort EFT. You've made an 18% return today.
Afternoon Dudio are you saying you've be confident of further investment at 5p but not at 5.86 ? Hardly a ringing endorsement. I'd encourage anyone who still believes to top up now - as news is long overdue and it must land in one form or another in the next month.
Rarely post, but just topped up today to bring down average price.
The science is there and surely RM must have a duty to respond to SH, unless hands tied by a 3rd party - read a lot of posts on here,but legal obligations?
Thanks in advance
Can the trolls keep on trolling? I really fancy topping up, but want the SP to drop below 5p again.
So, come on lads, do me favour will you?
Feels like a new era, 1 trade this morning.
Someone knows what is happening!
The CEO has got this covered!
"and more importantly shows incredible data to back up its patient identification techniques".
work for AZ after all. Like Sakura.
I would lower expectations that the company will share commercially sensitive information like this with just anyone. You could work for a competitor after all.
Thanks Elsol. Gloomy and realistic for where we are now - in this news vacuum. Things could still change dramatically for the better if Syn is about to tell us P2s are starting in H1:- and more importantly shows incredible data to back up its patient identification techniques. If we get a further non specific delay the game is up
Yes the Target Price estimate of 8p is not worth the paper its written on. For an analyst to issue an 8p/ share valuation today and was it c. £ 10/ share valuation in early 2021ish for the same underlying asset is crazy even given some material market changes and a delaying clinical knock back. On 'average' the analyst may have a better answer but lets see what evolves and how much of said upside we can capture alongside a greedy big pharma partner. .
Could you say that in English for the CSE Grade 2 Maths crowd please E
DB broker report appears v. v . prudent because they assume 50% probability of an IP fire sale (2m value) and 50% commercial DCF going concern value. But the 13 p/ shr of the go to market going concern is tiny tiny tiny value and looks held back. It was an optically aligned excel maths squeeze out. Plain and simple so disregard it IMHO. It's meaningless relative to the option value the this stock has now become.
Although Synairgen missed the H2 2023 suggestion. As far as I’m aware every other trial they’ve met near enough the timeframe they suggested, so that was very much an outlier.
I see no point in getting wound up about a deadline that as yet has not been missed.
If H1 2024 does not materialise I will expect a clear explanation and a disclosure of the plan and how much has been completed or an indication that they have partner negotiations which are subject to an NDA.
Simple silence will not suffice.
But as yet we are still in H1 and if the trials have not begun our finances should remain sound. So I remain calm waiting on either an update or the year end results.
One way or another we will soon have some answers.
A business operating as a going concern is expected to trade for 12 months or more without any threat of liquidation. Going concern means it does not appear that the company is at risk of closing due to insolvency but instead is expected to survive and thrive.
SNG have a decent cash balance, they may be short to complete
the trials if there is a delay, but I don't see an issue as a going concern
this year. Next year who knows!
I invested in Oxford Biomedica in the mid 90s. Alan and Sue Kingsman. Been a disaster!
"never materialised". I'd qualify that with a hefty "Yet".
My position has not moved DocDan. One outcome does not limit the other from being possible. I would assume that something is going on. And that they cannot update us yet.
Nice one Brand
"In addition to multinational pharmaceutical corporations, the UK has a thriving biotech sector renowned for innovation and entrepreneurship. Biotech companies like Oxford Biomedica, Synairgen, and Immunocore are at the forefront of developing cutting-edge therapies, including gene therapies, cell therapies, and immunotherapies."
https://valiantceo.com/the-pharmaceutical-industry-in-the-uk/
Edit again h1!